These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

855 related items for PubMed ID: 28404889

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Complex chromosome rearrangements may locate the bcr/abl fusion gene sites other than 22q11.
    Sessarego M, Fugazza G, Bruzzone R, Ballestrero A, Miglino M, Bacigalupo A.
    Haematologica; 2000 Jan; 85(1):35-9. PubMed ID: 10629589
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Diagnosis and Monitoring of Chronic Myeloid Leukemia: Chiang Mai University Experience.
    Tantiworawit A, Kongjarern S, Rattarittamrong E, Lekawanvijit S, Bumroongkit K, Boonma N, Rattanathammethee T, Hantrakool S, Chai-Adisaksopha C, Norasetthada L.
    Asian Pac J Cancer Prev; 2016 Jan; 17(4):2159-64. PubMed ID: 27221912
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring.
    Jabbour E, Kantarjian H.
    Am J Hematol; 2020 Jun; 95(6):691-709. PubMed ID: 32239758
    [Abstract] [Full Text] [Related]

  • 8. Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors: An Evolving Paradigm of Molecularly Targeted Therapy.
    Ali MA.
    Mol Diagn Ther; 2016 Aug; 20(4):315-33. PubMed ID: 27220498
    [Abstract] [Full Text] [Related]

  • 9. Reconsideration of BCR-ABL protein flow cytometric immunobead assay: how potent to diagnose and monitor chronic myeloid leukemia?
    Kelani R, Monem F.
    Int J Lab Hematol; 2015 Oct; 37(5):723-8. PubMed ID: 26059167
    [Abstract] [Full Text] [Related]

  • 10. Molecular cytogenetic characterization of Philadelphia-negative rearrangements in chronic myeloid leukemia patients.
    Bennour A, Bellâaj H, Ben Youssef Y, Elloumi M, Khelif A, Saad A, Sennana H.
    J Cancer Res Clin Oncol; 2011 Sep; 137(9):1329-36. PubMed ID: 21739181
    [Abstract] [Full Text] [Related]

  • 11. Analysis of Philadelphia chromosome-negative BCR-ABL-positive chronic myelogenous leukemia by hypermetaphase fluorescence in situ hybridization.
    Seong D, Kantarjian HM, Albitar M, Arlinghaus R, Xu J, Talpaz M, Rios MB, Guo JQ, O'Brien S, Siciliano M.
    Ann Oncol; 1999 Aug; 10(8):955-9. PubMed ID: 10509158
    [Abstract] [Full Text] [Related]

  • 12. Chronic Myeloid Leukemia with cryptic Philadelphia translocation and extramedullary B-lymphoid blast phase as an initial presentation.
    Soliman DS, Amer AM, Mudawi D, Al-Sabbagh Z, Alkuwari E, Al-Sabbagh A, Ibrahim F, Yassin MA.
    Acta Biomed; 2018 Apr 03; 89(3-S):38-44. PubMed ID: 29633732
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Cytogenetic response to imatinib treatment in Southern Brazilian patients with chronic myelogenous leukemia and variant Philadelphia chromosome.
    Koshiyama DB, Capra ME, Paskulin GA, Rosa RF, Oliveira CA, Vanelli T, Fogliatto LM, Zen PR.
    Ann Hematol; 2013 Jan 03; 92(2):185-9. PubMed ID: 23064942
    [Abstract] [Full Text] [Related]

  • 18. [Comparison of simultaneous bone marrow cytogenetic and peripheral blood molecular responses in chronic myeloid leukemia].
    Lai Y, Qin Y, Huang X, Jiang Q.
    Zhonghua Xue Ye Xue Za Zhi; 2014 Feb 03; 35(2):104-8. PubMed ID: 24606648
    [Abstract] [Full Text] [Related]

  • 19. Chronic myeloid leukemia: 2022 update on diagnosis, therapy, and monitoring.
    Jabbour E, Kantarjian H.
    Am J Hematol; 2022 Sep 03; 97(9):1236-1256. PubMed ID: 35751859
    [Abstract] [Full Text] [Related]

  • 20. Clinical implications of conventional cytogenetics, fluorescence in situ hybridization (FISH) and molecular testing in chronic myeloid leukaemia patients in the tyrosine kinase inhibitor era - A review.
    Ankathil R, Ismail SM, Mohd Yunus N, Sulong S, Husin A, Abdullah AD, Hassan R.
    Malays J Pathol; 2020 Dec 03; 42(3):307-321. PubMed ID: 33361712
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 43.